Cumberland Pharmaceuticals (NASDAQ:CPIX) Releases Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) announced its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, Zacks reports. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Cumberland Pharmaceuticals Stock Up 17.7 %

NASDAQ:CPIX traded up $0.91 on Tuesday, hitting $6.05. 401,060 shares of the company’s stock were exchanged, compared to its average volume of 849,869. The company has a market cap of $84.95 million, a P/E ratio of -7.86 and a beta of 0.12. The firm has a 50-day moving average price of $3.45 and a 200-day moving average price of $2.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. Cumberland Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $7.19.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals in a report on Friday, February 14th. They issued a “hold” rating on the stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.